Search

everythinglearnresearchcommunity

for

Search:↓

Diphenylcyclopropenone topical immunotherapy is effective for treating alopecia areata, with some side effects.

Rapamycin may help treat Leigh syndrome by targeting protein kinase C.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Targeted protein degraders show promise in treating cancer but need to target more diverse proteins.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.

CD8+ T cells are involved in alopecia areata and may cause disease relapse.

More precise, personalized therapies are needed for autoimmune diseases.

Baricitinib reduces inflammation and mitochondrial damage in skin cells.

TYK2 inhibitors show promise for treating cancer and autoimmune disorders.

Early detection, prevention, and proper management can reduce TB-IRIS complications and deaths in HIV patients.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

Some leukemia treatments can cause skin reactions similar to keratosis pilaris.

Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.

Stopping infliximab and using strong topical steroids can regrow hair lost due to psoriasiform alopecia.

Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.

Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.

Imatinib can cause hair loss due to lichen planopilaris.

The combination therapy is safe and more effective for treating pediatric facial and cervical vitiligo.

Iressa often causes skin issues like acne and dryness in lung cancer patients.

Steroid sulfatase inhibitors could help treat hormone-related disorders and cancers.

Type 1/17 inflammation in psoriasis increases skin cell growth due to a molecule that could be a new treatment target.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Modulating Cytochrome P450 activity could help develop new skin disease treatments.

Switching insulin brands caused skin lesions in a diabetic woman, resolved by changing to oral medication.

A woman with bullous pemphigoid had an allergic reaction to azathioprine, but got better with alternative treatments.

Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.

The treatment effectively promotes hair regrowth in androgenetic alopecia without causing skin irritation.